Kazia Therapeutics Ltd
KZIA9.790USD
0.000
Cierre 06/13, 16:00（ET）Cotizaciones retrasadas 15 min
32.59MCap. mercado
--P/E TTM
Más Datos de Kazia Therapeutics Ltd Compañía
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Información de la empresa
Símbolo de cotizaciónKZIA
Nombre de la empresaKazia Therapeutics Ltd
Fecha de salida a bolsaSep 01, 1994
Fundada en1994
Director ejecutivoDr. John E. Friend, M.D.
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalSep 01
DirecciónThree International Towers Level 24,
CiudadSYDNEY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísAustralia
Código postal2000
Teléfono1161298780088
Sitio Webhttps://www.kaziatherapeutics.com/
Símbolo de cotizaciónKZIA
Fecha de salida a bolsaSep 01, 1994
Fundada en1994
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 4 de mar
Divisa: USDActualizado: mar., 4 de mar
FY2022
FY2021
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: hace 14 horas
Actualizado: hace 14 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Chernett (Jorey)
10.09%
Barclays Capital Inc.
1.77%
UBS Financial Services, Inc.
0.39%
MAI Capital Management, LLC
0.06%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
87.67%
Accionistas
Accionistas
Proporción
Chernett (Jorey)
10.09%
Barclays Capital Inc.
1.77%
UBS Financial Services, Inc.
0.39%
MAI Capital Management, LLC
0.06%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
87.67%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
10.09%
Research Firm
1.77%
Investment Advisor
0.43%
Investment Advisor/Hedge Fund
0.08%
Hedge Fund
0.02%
Other
87.62%
Participación institucional
Actualizado: mar., 4 de mar
Actualizado: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
38
13.88K
1.02%
-25.51K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
2023Q1
33
27.66K
1.21%
-46.04K
2022Q4
36
43.17K
2.64%
-48.21K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Barclays Capital Inc.
24.00K
0.38%
+24.00K
--
Dec 31, 2024
UBS Financial Services, Inc.
5.51K
0.09%
+520.00
+10.42%
Dec 31, 2024
MAI Capital Management, LLC
27.84K
0.44%
+564.00
+2.07%
Dec 31, 2024
Rhumbline Advisers Ltd. Partnership
556.00
0.01%
--
--
Dec 31, 2024
Armistice Capital LLC
1.10K
0.02%
+1.10K
--
Sep 30, 2024
Osaic Holdings, Inc.
100.00
0%
+90.00
+900.00%
Dec 31, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Fecha
Tipo
Relación
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
